• Markets
    • icon
  • Companies
CU6 · ASX

Clarity Pharmaceuticals Ltd. (ASX:CU6)

AU$1.49

 0.01 (0.676%)
ASX:Live
05/12/2023 04:10:44 PM
Near Resistance (Realtime) Near Resistance Near 52 Week High HALO Price Momentum HALO Ords +3
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CU6 Overview

CU6 Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About CU6

Website

N/A

Telephone

61.2.9209.4037

Address

4 Cornwallis Street National Innovation Centre Eveleigh, New South Wales (NSW) 2015

Description

Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.

CU6 Price Chart

Key Stats

Market Cap

AU$356.37M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.68 - 1.5

Trade Value (12mth)

AU$69,374.00

1 week

14.62%

1 month

31.86%

YTD

52.04%

1 year

56.02%

All time high

1.71

Key Fundamentals

EPS 3 yr Growth

248.500%

EBITDA Margin

N/A

Operating Cashflow

-$27m

Free Cash Flow Return

-34.10%

ROIC

-30.50%

Interest Coverage

N/A

Quick Ratio

10.20

Other Data

Shares on Issue (Fully Dilluted)

260m

HALO Sector

Healthcare

Next Company Report Date

21-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CU6 Announcements

Latest Announcements

Date Announcements

31 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 May 22

Clarity adds innovative nanobody IP

×

Clarity adds innovative nanobody IP

31 May 22

Change of Director's Interest Notice - Rob Thomas

×

Change of Director's Interest Notice - Rob Thomas

31 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

30 September 22

Date of AGM

×

Date of AGM

30 November 23

undetectable PSA level with Cu-67 SAR-bisPSMA

×

undetectable PSA level with Cu-67 SAR-bisPSMA

30 November 23

Phase III CLARIFY trial in prostate cancer commences

×

Phase III CLARIFY trial in prostate cancer commences

30 November 23

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

30 January 23

Notification regarding unquoted securities - CU6

×

Notification regarding unquoted securities - CU6

30 December 21

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

30 December 21

Becoming a substantial holder

×

Becoming a substantial holder

29 September 23

Annual Report to shareholders

×

Annual Report to shareholders

29 September 23

Corporate Governance Statement

×

Corporate Governance Statement

29 September 21

Notice of Annual General Meeting

×

Notice of Annual General Meeting

29 November 23

SECuRE theranostic prostate cancer trial progresses

×

SECuRE theranostic prostate cancer trial progresses

29 June 22

Leading Australian cancer expert joins Clarity SAB

×

Leading Australian cancer expert joins Clarity SAB

29 June 22

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

29 December 21

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

29 April 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 October 22

Corporate Presentation - Wilsons Drug and Device Conference

×

Corporate Presentation - Wilsons Drug and Device Conference

28 November 23

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

28 November 23

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

28 November 23

Cleansing Notice

×

Cleansing Notice

28 March 23

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

28 March 23

Cleansing Notice

×

Cleansing Notice

CU6 Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.10 -0.09 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.10 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.7 -140.4 1.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.06 -0.09 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.05 -0.11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.3 -82.5 -54.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A -10.7 -15.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock N/A 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock N/A 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.08 0.36 0.27 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.08 0.36 0.27 Lock Lock Lock
     Growth % Lock Lock Lock Lock 148.5 351.7 -25.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 256 248 260 Lock Lock Lock
Basic m Lock Lock Lock Lock 256 248 260 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 13 30 36 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.1 -196.0 -117.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -13 -30 -36 Lock Lock Lock
     Growth % Lock Lock Lock Lock -37.3 -119.3 -21.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -14 -30 -36 Lock Lock Lock
     Growth % Lock Lock Lock Lock -37.2 -119.4 -22.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -13 -30 -34 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -3 -6 -10 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -10 -24 -25 Lock Lock Lock
     Growth % Lock Lock Lock Lock -47.0 -132.4 -3.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -8 -13 -27 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -27 3 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 11 87 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -8 -14 -28 Lock Lock Lock
     Growth % Lock Lock Lock Lock -13.0 -74.8 -103.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 19 92 65 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 23 100 77 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -19 -92 -65 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 8 8 Lock Lock Lock
Equity $m Lock Lock Lock Lock 20 92 69 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 20 92 69 Lock Lock Lock
     Growth % Lock Lock Lock Lock 148.5 354.9 -25.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -45.2 -23.8 -32.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -50.4 -25.8 -35.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -95.0 -52.7 -44.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -71.9 -42.2 -30.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -54.0 -23.7 -34.1 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.4 3.1 1.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -93.4 -100.1 -94.0 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 10.0 13.3 10.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 10.0 13.3 10.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 84.1 92.8 84.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -341.1 -177.4 -364.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -45.2 -23.8 -32.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -50.4 -25.8 -35.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock N/A 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock N/A -25.8 -35.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 4,484.0 12,126.2 10,339.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -4,484.0 -12,126.2 -10,339.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CU6 Shortsell

Frequently Asked Questions

The current share price of Clarity Pharmaceuticals Ltd. (CU6:ASX) is AU$1.49.
The 52-week high share price for Clarity Pharmaceuticals Ltd. (CU6:ASX) is AU$1.50.
The 52-week low share price for Clarity Pharmaceuticals Ltd. (CU6:ASX)? is AU$0.68.
Clarity Pharmaceuticals Ltd. (CU6:ASX) does not pay a dividend.
Clarity Pharmaceuticals Ltd. (CU6:ASX) does not pay a dividend.
Clarity Pharmaceuticals Ltd. (CU6:ASX) has a franking level of 0%.
Clarity Pharmaceuticals Ltd. (CU6:ASX) is classified in the Healthcare.
The current P/E ratio for Clarity Pharmaceuticals Ltd. (CU6:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.